Literature DB >> 3495201

Comparison of recombinant human immunodeficiency virus gag precursor and gag/env fusion proteins and a synthetic env peptide as diagnostic reagents.

R L Shoeman, D Young, R Pottathil, J Victor, R R Conroy, R M Crowl, T Coleman, E Heimer, C Y Lai, K Ganguly.   

Abstract

Diagnostic reagents for detection of human immunodeficiency virus (HIV) exposure with improved reliability may be provided by viral encoded proteins produced by recombinant DNA techniques or by synthetic peptides corresponding to appropriate viral epitopes. We have expressed at high levels in E. coli a gag gene segment corresponding to approximately 97% of the p55 gag precursor protein, as well as a novel gag/env fusion protein that contains antigenic determinants in common with gag p24, env gp41, and env gp120. The gag and gag/env proteins were purified from insoluble inclusion bodies by sequential extraction with increasing concentrations of urea. These components were tested for reactivity with antisera to HIV proteins and peptides. We have also chemically synthesized a peptide corresponding to env residues 578-608, representing a portion of env gp41. The final preparation of gag and gag/env proteins in 8 M urea reacted with sheep anti-HTLV-III p24 gag antibodies and acquired immune deficiency syndrome (AIDS) patient sera. The gag/env fusion protein also reacted with rabbit anti-HIV env 500-511 peptide antibody. Both recombinant proteins and the env peptide were suitable as reagents for evaluation of serum samples by enzyme-linked immunosorbent assay (ELISA). Results of ELISA assays utilizing the recombinant viral proteins and synthetic peptide were in good agreement with results obtained using disrupted virus as antigen in ELISA assays and immunoblotting.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3495201     DOI: 10.1016/0003-2697(87)90465-9

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  5 in total

1.  New sensitive and specific assay for human immunodeficiency virus antibodies using labeled recombinant fusion protein and time-resolved fluoroimmunoassay.

Authors:  H Siitari; P Turunen; J Schrimsher; M Nunn
Journal:  J Clin Microbiol       Date:  1990-09       Impact factor: 5.948

2.  Reversal of human immunodeficiency virus type 1 protein-induced inhibition of natural killer cell activity by alpha interferon and interleukin-2.

Authors:  M P Nair; S A Schwartz
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

3.  Use of TrpE/Gag fusion proteins to characterize immunoreactive domains on the human immunodeficiency virus type 1 core protein.

Authors:  M G Windheuser; G E Tegtmeier; C Wood
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

4.  Immunoregulatory activities of human immunodeficiency virus (HIV) proteins: effect of HIV recombinant and synthetic peptides on immunoglobulin synthesis and proliferative responses by normal lymphocytes.

Authors:  M P Nair; R Pottathil; E P Heimer; S A Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

5.  Immunoregulatory effects of morphine on human lymphocytes.

Authors:  M P Nair; S A Schwartz; R Polasani; J Hou; A Sweet; K C Chadha
Journal:  Clin Diagn Lab Immunol       Date:  1997-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.